{"title":"烟灰素通过抑制炎症和阻断MAPK/NF-κB通路改善大鼠干眼模型。","authors":"Dan Zhu, Xiao-Yang Wu, Liang-Chang Li","doi":"10.18240/ijo.2025.08.02","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To investigate the functions and potential mechanisms of obtusifolin in dry eye disease (DED) in a rat model.</p><p><strong>Methods: </strong>A rat DED model was established <i>via</i> topical administration of benzalkonium chloride (BAC), followed by administration of obtusifolin. Conjunctival irritation score and tear production were measured to evaluate DED symptoms. Enzyme-linked immunosorbent assay (ELISA) was employed for determining inflammatory cytokine levels in rat conjunctiva. Periodic acid-Schiff staining and corneal fluorescein staining were implemented for assessing goblet cell numbers and corneal epithelial defects, respectively. Western blotting showed zonula occludens-1 (ZO-1), matrix metalloproteinase-9 (MMP-9), and mitogen-activated protein kinase (MAPK)/nuclear factor kappa B (NF-κB) signaling-related protein levels in the conjunctiva.</p><p><strong>Results: </strong>Topical application of obtusifolin alleviated conjunctival irritation and enhanced tear production in BAC-induced DED rats. Obtusifolin attenuated conjunctival inflammatory response and goblet cell loss as well as corneal epithelial barrier disruption in DED rats. Obtusifolin suppressed extracellular signal-regulated kinase (ERK), p38, and NF-κB phosphorylation in the conjunctiva of DED rats.</p><p><strong>Conclusion: </strong>Obtusifolin ameliorates DED in rats possibly by alleviating inflammation <i>via</i> the inactivation of MAPK/NF-κB signaling.</p>","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 8","pages":"1426-1432"},"PeriodicalIF":1.8000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12311460/pdf/","citationCount":"0","resultStr":"{\"title\":\"Obtusifolin ameliorates dry eye model in rats by reducing inflammation and blocking MAPK/NF-κB pathways.\",\"authors\":\"Dan Zhu, Xiao-Yang Wu, Liang-Chang Li\",\"doi\":\"10.18240/ijo.2025.08.02\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To investigate the functions and potential mechanisms of obtusifolin in dry eye disease (DED) in a rat model.</p><p><strong>Methods: </strong>A rat DED model was established <i>via</i> topical administration of benzalkonium chloride (BAC), followed by administration of obtusifolin. Conjunctival irritation score and tear production were measured to evaluate DED symptoms. Enzyme-linked immunosorbent assay (ELISA) was employed for determining inflammatory cytokine levels in rat conjunctiva. Periodic acid-Schiff staining and corneal fluorescein staining were implemented for assessing goblet cell numbers and corneal epithelial defects, respectively. Western blotting showed zonula occludens-1 (ZO-1), matrix metalloproteinase-9 (MMP-9), and mitogen-activated protein kinase (MAPK)/nuclear factor kappa B (NF-κB) signaling-related protein levels in the conjunctiva.</p><p><strong>Results: </strong>Topical application of obtusifolin alleviated conjunctival irritation and enhanced tear production in BAC-induced DED rats. Obtusifolin attenuated conjunctival inflammatory response and goblet cell loss as well as corneal epithelial barrier disruption in DED rats. Obtusifolin suppressed extracellular signal-regulated kinase (ERK), p38, and NF-κB phosphorylation in the conjunctiva of DED rats.</p><p><strong>Conclusion: </strong>Obtusifolin ameliorates DED in rats possibly by alleviating inflammation <i>via</i> the inactivation of MAPK/NF-κB signaling.</p>\",\"PeriodicalId\":14312,\"journal\":{\"name\":\"International journal of ophthalmology\",\"volume\":\"18 8\",\"pages\":\"1426-1432\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12311460/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.18240/ijo.2025.08.02\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.08.02","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Obtusifolin ameliorates dry eye model in rats by reducing inflammation and blocking MAPK/NF-κB pathways.
Aim: To investigate the functions and potential mechanisms of obtusifolin in dry eye disease (DED) in a rat model.
Methods: A rat DED model was established via topical administration of benzalkonium chloride (BAC), followed by administration of obtusifolin. Conjunctival irritation score and tear production were measured to evaluate DED symptoms. Enzyme-linked immunosorbent assay (ELISA) was employed for determining inflammatory cytokine levels in rat conjunctiva. Periodic acid-Schiff staining and corneal fluorescein staining were implemented for assessing goblet cell numbers and corneal epithelial defects, respectively. Western blotting showed zonula occludens-1 (ZO-1), matrix metalloproteinase-9 (MMP-9), and mitogen-activated protein kinase (MAPK)/nuclear factor kappa B (NF-κB) signaling-related protein levels in the conjunctiva.
Results: Topical application of obtusifolin alleviated conjunctival irritation and enhanced tear production in BAC-induced DED rats. Obtusifolin attenuated conjunctival inflammatory response and goblet cell loss as well as corneal epithelial barrier disruption in DED rats. Obtusifolin suppressed extracellular signal-regulated kinase (ERK), p38, and NF-κB phosphorylation in the conjunctiva of DED rats.
Conclusion: Obtusifolin ameliorates DED in rats possibly by alleviating inflammation via the inactivation of MAPK/NF-κB signaling.
期刊介绍：
· International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication
and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online).
This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from
WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed,
PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166.
IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific
Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO);
Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President,
Chinese Academy of Engineering.
International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of
blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of
AAO/PAAO) et al.
Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of
Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and
Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society).
Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press).
Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and
Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics).
Associate Editors-in-Chief include:
Prof. Ning-Li Wang (President Elect of APAO);
Prof. Ke Yao (President of Chinese Ophthalmological Society) ;
Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ;
Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA);
Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society);
Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA);
Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA).
IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles,
both basic and clinical papers.
Instruction is Welcome Contribution is Welcome Citation is Welcome
Cooperation organization
International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
